AUTL - Autolus Therapeutics plc
| Previous Close | 21.98 |
| Open | 21.92 |
| Bid | 21.02 x 1000 |
| Ask | 24.60 x 1200 |
| Day's Range | 20.30 - 23.27 |
| 52 Week Range | 19.17 - 53.24 |
| Volume | 411,545 |
| Avg. Volume | 95,241 |
| Market Cap | 978.708M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.40 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.00 |
- ACCESSWIRE•9 days ago
Autolus Therapeutics Plc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 14, 2019 / Autolus Therapeutics Plc (NASDAQ: AUTL ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 8:30 AM ...
- GlobeNewswire•9 days ago
Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
LONDON, May 14, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- GlobeNewswire•15 days ago
Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
LONDON, May 07, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- Insider Monkey•23 days ago
Is Autolus Therapeutics plc (AUTL) A Good Stock To Buy?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- GlobeNewswire•29 days ago
Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to autologous enriched T-cells genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 (AUTO3) for the treatment of acute lymphoblastic leukemia (ALL).
- GlobeNewswire•last month
Autolus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
LONDON, April 15, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- Simply Wall St.•last month
What Kind Of Shareholder Owns Most Autolus Therapeutics plc (NASDAQ:AUTL) Stock?
If you want to know who really controls Autolus Therapeutics plc (NASDAQ:AUTL), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend...
- Zacks•last month
Autolus Therapeutics (AUTL) Catches Eye: Stock Jumps 5.6%
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- GlobeNewswire•last month
Autolus Announces Pricing of Public Offering
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in the United States of 4,200,000 American Depositary Shares (“ADSs”) representing 4,200,000 ordinary shares at a public offering price of $24.00 per ADS, for total gross proceeds of approximately $100.8 million. All ADSs sold in the offering were offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 630,000 ADSs at the public offering price, less underwriting discounts and commissions.
- GlobeNewswire•last month
Autolus Announces Proposed Public Offering in the United States
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it intends to offer and sell 4,000,000 American Depositary Shares (“ADSs”) representing 4,000,000 ordinary shares in an underwritten public offering in the United States. Autolus also intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 ADSs at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.
- PR Newswire•2 months ago
Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR
Arix Bioscience plc (ARIX.L) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Autolus Therapeutics plc (AUTL) ("Autolus"), has announced that Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London (UCL), presented today initial data from the ongoing Phase 1/2 ALLCAR19 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL) as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. The announcement can be accessed on Autolus' investor website at https://www.autolus.com/investor-relations and full text of the announcement from Autolus is contained below.
- GlobeNewswire•2 months ago
Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London (UCL), presented today initial data from the ongoing Phase 1/2 ALLCAR19 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL) as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. Relapsed / refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in adults is an area of significant unmet clinical need.
- PR Newswire•2 months ago
Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
LONDON , March 29, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes ...
- GlobeNewswire•2 months ago
Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
LONDON, March 29, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the.
- GlobeNewswire•2 months ago
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
LONDON, March 26, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the.
- GlobeNewswire•2 months ago
Autolus Therapeutics to Host R&D Day on March 26, 2019
Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications Program and webcast to begin at 8:00 am ET.
- GlobeNewswire•3 months ago
Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
LONDON, March 04, 2019 -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- GlobeNewswire•3 months ago
Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019
LONDON, March 04, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
- GlobeNewswire•3 months ago
Vineti announces strategic partnership with Autolus Therapeutics to support delivery of novel T cell therapies
Vineti Inc, the leading software platform of record for personalized therapeutics, today announced a new partnership to help advance and scale Autolus Therapeutics plc (AUTL)’s broad clinical stage pipeline of cancer treatments for hematological and solid tumors. Autolus, a clinical-stage global biopharmaceutical company developing next-generation programmed T cell therapies, has four clinical programs in five hematological and one solid tumor indication. Vineti provides the leading software platform to align, streamline, and manage the complex personalized cell therapy process to enhance safety and efficiency of product delivery.
- PR Newswire•3 months ago
Autolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to December 31, 2018
- Conference Call to be held on February 25, 2019 at 8:00 am EST/1:00 pm GMT - LONDON , Feb. 25, 2019 /PRNewswire/ -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company ...
- PR Newswire•3 months ago
Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019
LONDON , Feb. 21, 2019 /PRNewswire/ -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, ...
- PR Newswire•3 months ago
Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial
LONDON , February 19, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, notes that its portfolio company, ...
- PR Newswire•3 months ago
Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris
Updated results confirm AUTO1 data from ASH 2017 No severe cytokine release syndrome (Grade 3-5) 86% molecular complete response rate after a single dose of AUTO1 LONDON , Feb. 19, 2019 /PRNewswire/ -- Autolus ...
- Zacks•4 months ago
Alexandria Fully Leases New Built-to-Suit Facility to Autolus
Alexandria Real Estate Equities' (ARE) new build-to-suit project in Rockville will serve as the U.S. headquarters and a commercial scale manufacturing site for Autolus.
- American City Business Journals•4 months ago
Biotech to create 170 jobs, invest $28M in new Rockville HQ
London-based Autolus Therapeutics said Monday it plans to create up to 170 jobs at its new U.S. headquarters and manufacturing facility in Rockville over the next three years and invest about $28 million in the 85,000-square-foot project planned for the Shady Grove Life Sciences Center. The project will get a boost from a $200,000 Economic Development Fund conditional grant from the county, while the state of Maryland is providing a $525,000 Advantage Maryland conditional loan. Autolus' new Montgomery County facility is part of a plan by the company to roughly double its work force from 200 employees today to nearly 400 in the next 12 to 18 months, said Matthias Alder, senior vice president and chief business officer of Autolus, who is leading efforts to establish the new headquarters.
